Indication

Poorly Differentiated Neuroendocrine Carcinomas

1 clinical trial

1 product

Clinical trial

EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors

Status: Completed, Estimated PCD: 2023-12-20

Product